Generics 1

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Vinorelbine manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : Germany

Clear all

1 products found

vinorelbine

Concentrate for solution for infusion 10 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Registered in
Germany
Available for
Licensing with supply, Distribution only
Manufacturer #16717
They've been serving and assisting customers in the healthcare business in Regulatory Affairs and Pharmacovigilance for over 30 years. This sphere of action covers many countries around the world. They look after their local and European consumers and the supply chain by providing high-quality products for internationalization strategies.

Manufacturer usually replies in 14 days

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

What is the Vinorelbine drug?

Vinorelbine is a third-generation vinca alkaloid. It is used as a chemotherapy medication to treat several types of cancers, such as breast cancer and non-small cell lung cancer. Vinorelbine disrupts the normal function of microtubules and stops cell division.
Vinorelbine was created by Pierre Potier at the CNRS in France in the 80s. The Vinorelbine drug was approved in France in 1989 and 1994 by the FDA. In 2003, the US agreed on marketing generics for Vinorelbine.
Vinorelbine medicine is on the World Health Organization's List of Essential Medicines. In most European countries, the use of Vinorelbine is allowed to treat non-small cell lung cancer and breast cancer. In the United States, it is approved only for non-small cell lung cancer.

Vinorelbine manufacturers and wholesalers:

Vinorelbine has several brand names. Vinorelbine medicine is known as Navelbine in the US and France. The first Vinorelbine manufacturer was Pierre Fabre Medicament. But now, the Vinorelbine medicine has many manufacturers such as Actavis Totowa Llc, App Pharmaceuticals Llc, Baxter Healthcare Corp Anesthesia and Critical Care, Bedford Laboratories, Ebewe Pharma, Hospira Inc, Teva Parenteral Medicines Inc.
Vinorelbine suppliers market it in the form of an oral solution or solution for injection. For the intravenous solution, Vinorelbine is available in 10 mg/mL and 50 mg/5 mL for Generics and Navelbine.

Vinorelbine for sales:

For 1 milliliter of Vinorelbine in the US, it costs from $24.62 to $30.50 and for 5 milliliters Vinorelbine costs from $17.02 to $85.10. Under the name Navelbine, one 50 mg/5 ml vial costs from $27.6 to $42.0.
As Vinorelbine is available globally, fraudulent online pharmacies may attempt to sell an illegal generic version of Vinorelbine. Thanks to Pipelinepharma online marketplace, you can be sure of the qualifications of the Vinorelbine sellers because they all have been through quality control procedures. Plus, being sure your future partner is qualified, you will save time sourcing for the product and buyer or seller, because it is all in one safe place: Pipelinepharma B2B marketplace. On the platform, you can easily place orders for any pharmaceutical products, including Vinorelbine. From our online marketplace, Vinorelbine is mostly available from Argentina, China, India, and Taiwan.

How to use Vinorelbine drugs?

To treat breast cancer, an adult should take IV: 25 mg/m2 every seven days. It is highly recommended for pregnant women not to take the Vinorelbine drug.
Taking Vinorelbine can cause some side effects such as bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, soreness, stinging, swelling, tenderness, blood in the urine.
Vinorelbine vials should be stored at 2°C to 8°C and not be frozen.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation